IMGO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 Jan 2023 @ 16:00):

Stats
Today's Volume	138 127
Average Volume	762 778
Market Cap	0.00
EPS	$-0.500 ( 2022-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.674 (1.87%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-11	Keating Laurie	Sell	11 904	Stock Option (Right to Buy)
2023-01-11	Kariuki Enoch	Sell	11 904	Stock Option (Right to Buy)
2023-01-11	Tapper Amy E.	Sell	141 094	Common Stock
2023-01-11	Tapper Amy E.	Sell	103 000	Stock Option (Right to Buy)
2023-01-11	Rienhoff Hugh Jr	Sell	501 702	Common Stock

INSIDER POWER
-50.63
Last 100 transactions
Buy: 1 323 458 \| Sell: 3 917 808

Volume Correlation

Long: 0.25 (neutral)

Short: 0.21 (neutral)

Signal:(86.307) Neutral

Imago BioSciences, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Imago BioSciences, Inc. Correlation - Currency/Commodity

0.40
( neutral )

0.32
( neutral )

0.68
( moderate )

-0.87
( strong negative )

0.20
( neutral )

-0.10
( neutral )

Imago BioSciences, Inc. Financials

Annual	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.16

Q3	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.520

Q2	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.410

Q1	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.490

Financial Reports:

No articles found.

Imago BioSciences, Inc.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.